The search textbox has an autosuggest feature. When you enter three or more characters,
a list of up to 10 suggestions will popup under the textbox. Use the arrow keys
to move through the suggestions. To select a suggestion, hit the enter key. Using
the escape key closes the listbox and puts you back at the textbox. The radio buttons
allow you to toggle between having all search items start with or contain the text
you entered in the search box.
dHER2+AS15 vaccine
A cancer vaccine consisting of a truncated recombinant HER2/neu peptide (dHER2) combined with the immunoadjuvant AS15 with potential immunostimulatory and antineoplastic activities. Upon administration, dHER2+AS15 vaccine may stimulate the host immune response to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells that overexpress the HER2/neu protein, resulting in tumor cell lysis. The tumor-associated antigen (TAA) HER2/neu is often overexpressed by a variety of tumor cell types; dHER2 includes amino acids 1-645 or 1-653 of the extracellular domain (ECD) and an immunogenic carboxyl terminal autophosphorylation portion of the intracellular domain (ICD). AS15 is an adjuvant formulation that contains the adjuvant systems AS01B and AS07A; AS01 B is composed of liposomes containing 3D-MPL and QS21 and AS07A is composed of the synthetic oligodeoxynucleotide (ODN) Toll-like receptor-9 (TLR9) agonist CpG 7909. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| Synonyms: | | dHER2+AS15 antigen-specific cancer immunotherapeutic dHER2+AS15 ASCI | |
| |||
